Literature DB >> 25187642

Cumulative inflammation associates with asymmetric dimethylarginine in rheumatoid arthritis: a 6 year follow-up study.

Aamer Sandoo1, Theodoros Dimitroulas2, James Hodson3, Jacqueline P Smith3, Karen M Douglas3, George D Kitas1.   

Abstract

OBJECTIVE: The aim of the present study was to investigate the associations of cumulative inflammatory burden (assessed by serial measurements of inflammatory markers) and classical cardiovascular disease (CVD) risk factors with asymmetric dimethylarginine (ADMA) in a large prospective cohort of patients with established RA.
METHODS: Two hundred and one RA patients [155 females, median age 67 years (range 59-73)] were assessed at baseline (2006) for the presence of classical CVD risk factors and determination of systemic inflammation by CRP and ESR. Global CVD risk was identified by the Framingham Risk Score and the Reynolds Risk Score. At follow-up (2012), ADMA levels were measured by ELISA. A quarterly measurement of CRP and ESR for each year the patient was in the study was used to produce an average area under the curve (AAUC) for ESR and CRP.
RESULTS: Regression analysis revealed that baseline ESR in 2006 and the AAUC of ESR and CRP all had significant positive relationships with current ADMA (P = 0.004, P < 0.001 and P = 0.002, respectively). Baseline CRP in 2006 was not a significant predictor of ADMA (P = 0.093), although this relationship was in the same direction as the other factors. These results remained consistent after adjustment for classical CVD risk factors.
CONCLUSION: Cumulative inflammatory burden is positively associated with ADMA levels, suggesting a potential pathogenic mechanism through which chronic systemic inflammation exerts deleterious effects on nitric oxide metabolism and endothelial homeostasis. This association is independent of classical CVD risk factors.
© The Author 2014. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  ADMA; CVD risk; atherosclerosis; endothelial dysfunction; inflammation; rheumatoid arthritis

Mesh:

Substances:

Year:  2014        PMID: 25187642     DOI: 10.1093/rheumatology/keu349

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  13 in total

Review 1.  Cardiovascular risk in rheumatoid arthritis: assessment, management and next steps.

Authors:  Thomas Zegkos; George Kitas; Theodoros Dimitroulas
Journal:  Ther Adv Musculoskelet Dis       Date:  2016-04-30       Impact factor: 5.346

Review 2.  Cardiovascular comorbidity in rheumatic diseases.

Authors:  Michael T Nurmohamed; Maaike Heslinga; George D Kitas
Journal:  Nat Rev Rheumatol       Date:  2015-08-18       Impact factor: 20.543

3.  Effect of statin on arginine metabolites in treated HIV-infection.

Authors:  Sahera Dirajlal-Fargo; Vanessa El Kamari; Abdus Sattar; Khurshid Alam; Nicholas Funderburg; Danielle Labbato; Lisa Pirro; Chris T Longenecker; Wai Hong Wilson; Grace A McComsey
Journal:  Atherosclerosis       Date:  2017-09-28       Impact factor: 5.162

Review 4.  Asymmetric Dimethyl Arginine as a Biomarker of Atherosclerosis in Rheumatoid Arthritis.

Authors:  Manuela Di Franco; Bruno Lucchino; Fabrizio Conti; Guido Valesini; Francesca Romana Spinelli
Journal:  Mediators Inflamm       Date:  2018-01-18       Impact factor: 4.711

5.  Elevated levels of plasma symmetric dimethylarginine and increased arginase activity as potential indicators of cardiovascular comorbidity in rheumatoid arthritis.

Authors:  Unnikrishnan M Chandrasekharan; Zeneng Wang; Yuping Wu; W H Wilson Tang; Stanley L Hazen; Sihe Wang; M Elaine Husni
Journal:  Arthritis Res Ther       Date:  2018-06-08       Impact factor: 5.156

Review 6.  Role of the eNOS Uncoupling and the Nitric Oxide Metabolic Pathway in the Pathogenesis of Autoimmune Rheumatic Diseases.

Authors:  Anna Łuczak; Marta Madej; Agata Kasprzyk; Adrian Doroszko
Journal:  Oxid Med Cell Longev       Date:  2020-04-13       Impact factor: 6.543

7.  Symmetric Dimethylarginine Is Not Associated with Cumulative Inflammatory Load or Classical Cardiovascular Risk Factors in Rheumatoid Arthritis: A 6-Year Follow-Up Study.

Authors:  Theodoros Dimitroulas; James Hodson; Aamer Sandoo; Jacqueline P Smith; Karen M Douglas; George D Kitas
Journal:  Mediators Inflamm       Date:  2015-10-12       Impact factor: 4.711

8.  Effect of alpha-lipoic acid on asymmetric dimethylarginine and disability in multiple sclerosis patients: A randomized clinical trial.

Authors:  Mohammad Khalili; Madjid Soltani; Shirin Amiri Moghadam; Parvin Dehghan; Amirreza Azimi; Omid Abbaszadeh
Journal:  Electron Physician       Date:  2017-07-25

9.  Endothelial injury in rheumatoid arthritis: a crosstalk between dimethylarginines and systemic inflammation.

Authors:  Theodoros Dimitroulas; James Hodson; Aamer Sandoo; Jacqueline Smith; George D Kitas
Journal:  Arthritis Res Ther       Date:  2017-02-10       Impact factor: 5.156

Review 10.  The Role of Statins in Disease Modification and Cardiovascular Risk in Rheumatoid Arthritis.

Authors:  Stergios Soulaidopoulos; Elena Nikiphorou; Theodoros Dimitroulas; George D Kitas
Journal:  Front Med (Lausanne)       Date:  2018-02-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.